The first immune checkpoint to be identified in treating cancer was cytotoxic T lymphocyte-associated protein 4 (CTLA-4), which competes with the costimulatory molecule CD28 for ligands CD80 and/or CD86 (collectively known as B7 ligands) [19,87]. This evidence concerns the gene CD80 and cancer.